All In Biotech

NDA 020353 · Twi Pharms

Naprelan

Naproxen Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jan 5, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

356

90 Phase 3, 11 recruiting

FAERS reports

13,985

10,751 serious, 3,931 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ( 5.1 )]. Naproxen Sodium Controlled-Release Tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] . Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms....

What it is approved for

From the label in effect Oct 14, 2026.

Naproxen Sodium Controlled-Release Tablets are indicated for the treatment of: rheumatoid arthritis (RA) osteoarthritis (OA) ankylosing spondylitis (AS) tendinitis, bursitis acute gout primary dysmenorrhea (PD) the relief of mild to moderate pain [ see Warnings and Precautions ( 5 ) ]. Naproxen Sodium Controlled-Release Tablets is a nonsteroidal anti-inflammatory drug indicated for the treatment of: rheumatoid arthritis (RA)( 1 ) osteoarthritis (OA)( 1 ) ankylosing spondylitis (AS)( 1 ) tendinitis, bursitis ( 1 ) acute gout ( 1 ) primary dysmenorrhea (PD)( 1 ) the relief of mild to moderate pain ( 1 )

Mechanism: Naproxen has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of naproxen sodium, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Naproxen sodium is a potent inhibitor of prostaglandin synthesis in vitro . Naproxen sodium concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because naproxen sodium is an inhibitor of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NAPRELAN · NAPROXEN SODIUM EQ 500MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • NAPRELAN · NAPROXEN SODIUM EQ 750MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • NAPRELAN · NAPROXEN SODIUM EQ 375MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.

All 356 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,011
  • fatigue2,757
  • off label use2,620
  • pain2,616
  • rash2,391
  • arthralgia2,341
  • diarrhoea2,328
  • vomiting2,269
  • condition aggravated2,199
  • joint swelling2,197
  • synovitis2,148
  • fibromyalgia2,142

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004115
2005159
200673
200757
2008171
2009123
2010151
2011374
20121,169
2013248
2014243
2015318
2016498
2017512
2018536
2019769
2020744
2021674
20221,002
20231,153
20242,036
20252,056
2026803

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Naprelan (Naproxen Sodium)

2024 spending

$69K

Beneficiaries

15

46 claims

Per beneficiary

$4,574

$20.06 per unit

View as table
YearSpending
2020$483,261
2021$274,223
2022$212,815
2023$123,017
2024$68,603

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,373 on PubMed

Sponsor: Twi Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.